A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.

Study Overview

• Status: Terminated
• Conditions: Sjögrens Disease
• Intervention / Treatment: Drug: Abiprubart; Drug: Placebo

Detailed Description

This is a 56-week (24-week randomized double-blind period, 24-week active treatment period, and 8-week safety follow-up period) multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of abiprubart in participants with Sjögren's Disease with moderate or high systemic disease activity according to the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI). The objectives of the study are to evaluate efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of abiprubart compared with placebo across the estimated therapeutic range using different dosing regimens of abiprubart.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Menifee, California, United States, 92586
      • Medvin Clinical Research
    • Poway, California, United States, 92064
      • Biosolutions Clinical Research Center
    • Whittier, California, United States, 90602
      • Medvin Clinical Research
  • Florida
    • Daytona Beach, Florida, United States, 32117
      • International Medical Research
    • DeBary, Florida, United States, 32713
      • Omega Research Debary, LLC
  • Illinois
    • Schaumburg, Illinois, United States, 60195
      • Greater Chicago Specialty Physicians/ Clinical Investigation Specialists
    • Skokie, Illinois, United States, 60076
      • Clinic of Robert Hozman, MD/Clinical Investigation Specialists, Inc.
    • Springfield, Illinois, United States, 62702
      • Springfield Clinic Rheumatology
  • Louisiana
    • Lake Charles, Louisiana, United States, 70605
      • Accurate Clinical Research, Inc
  • North Carolina
    • Salisbury, North Carolina, United States, 28144
      • Accellacare (Salisbury)
    • Wilmington, North Carolina, United States, 28401
      • Carolina Arthritis Associates
  • Texas
    • Allen, Texas, United States, 75013
      • Arthritis and Rheumatology Research Institute, PLLC
    • Corpus Christi, Texas, United States, 78415
      • Arthritis Care of Texas
    • Plano, Texas, United States, 75024
      • Trinity Universal Research Associates, Inc.
    • San Antonio, Texas, United States, 78215
      • Sun Research Institute
    • Waco, Texas, United States, 76710
      • Arthritis & Osteoporosis Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Has a diagnosis of Sjögren's Disease according to 2016 American College or Rheumatology (ACR)-EULAR Classification Criteria.
• Has ESSDAI value ≥ 5, counting only the biological, hematological, articular, cutaneous, glandular, lymphadenopathy, and constitutional organ domains at Screening.
• Is seropositive at Screening for anti-Sjögren's-syndrome-related antigen A autoantibodies (SSA) antibodies tested at a central laboratory.
• Has stimulated whole salivary flow rate at Screening of ≥ 0.05 mL/min
• Weighs at least 40 kg and no more than 150 kg and has a body mass index (BMI) within the range of 18-40 kg/m2.

Exclusion Criteria:

• Prior exposure to any other anti-CD40/CD154 agent.
• Diagnosis of Sjögren's Disease overlap syndromes where another autoimmune rheumatic disease constitutes the principal illness, including fibromyalgia with currently active, inadequately controlled symptoms.
• Has received cataract surgery, Lasik, or other ophthalmologic surgery procedure (e.g., lachrymal plug) in the 6 months prior to Screening.
• Injectable corticosteroids (including intra-articular) within 8 weeks prior to randomization.
• Has started, stopped or adjusted dose/regimen of medications for treatment of, or known to cause dry mouth/eyes within the 30 days prior to screening or is anticipating change to these treatment regimens during the study.
• Has history of immunodeficiency (e.g., immune disorders or disorders that result in decreased immunity), including human immunodeficiency virus (HIV).
• History of thromboembolic event or a significant risk of future thromboembolic events.
• Has a known high risk of infection; Has a history of chronic or recurrent infectious disease; Has any known or suspected active infection, or has had a serious infection requiring hospitalization, or has been treated with IV/IM antibiotics for an infection within 8 weeks prior to first dose of study drug or treatment with oral antibiotics for an infection within 2 weeks prior to first dose of study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Abiprubart 400mg SC q2wk; Part A: Loading dose of abiprubart 800 mg subcutaneous (SC) followed by abiprubart 400 mg SC every 2 weeks (q2wk) through Week 22. Part B: Abiprubart 400 mg SC q2wk: abiprubart 400 mg SC q2wk up to and including Week 46.	Drug: Abiprubart; humanized monoclonal antibody; Other Names: KPL-404
Experimental: Abiprubart 400mg SC q4wk; Part A: Loading dose of abiprubart 800 mg SC followed by abiprubart 400 mg SC q2wk through Week 22 which will alternately administer placebo or abiprubart to provide active drug every 4 weeks (q4wk) while maintaining treatment concealment. Part B: Abiprubart 400 mg SC q4wk: abiprubart 400 mg SC q2wk up to and including Week 46 which will alternately administer placebo or abiprubart to provide active drug q4wk while maintaining treatment concealment.	Drug: Abiprubart; humanized monoclonal antibody; Other Names: KPL-404; Drug: Placebo; sterile preservative-free solution
Placebo Comparator: Placebo; Part A: A matched volume placebo loading dose followed by placebo SC injections q2wk through Week 22. Part B: Participants assigned to placebo in Part A will transition to active abiprubart treatment, according to randomized assignment, with either abiprubart 400 mg SC q2wk or abiprubart 400 mg SC q4wk.	Drug: Abiprubart; humanized monoclonal antibody; Other Names: KPL-404; Drug: Placebo; sterile preservative-free solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Week 24	Baseline, Week 24

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of Sjögren's Tool for Assessing Response (STAR) Responders (≥ 5 points) at Week 24	Week 24
Proportion of STAR Responders (≥ 5 points) Over Time	Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in Stimulated Salivary Flow Rate (mL/min) at Week 24	Baseline, Week 24
Change From Baseline in Stimulated Salivary Flow Rate (mL/min) Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in Unstimulated Salivary Flow Rate (mL/min) at Week 24	Baseline, Week 24
Change From Baseline in Unstimulated Salivary Flow Rate (mL/min) Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in EULAR Sjögren's Syndrome Disease Patient Reported Index (ESSPRI) at Week 24	Baseline, Week 24
Change From Baseline in ESSPRI Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in Schirmer's Test at Week 24	Baseline, Week 24
Change From Baseline in Schirmer's Test Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in Clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) at Week 24	Baseline, Week 24
Change From Baseline in clinESSDAI Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) at Week 24	Baseline, Week 24
Change From Baseline in FACIT-Fatigue Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56
Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D 5L) at Week 24	Baseline, Week 24
Change From Baseline in EQ-5D 5L Over Time	Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 56

Collaborators and Investigators

• Sponsor: Kiniksa Pharmaceuticals International, plc
• Collaborators: Kiniksa Pharmaceuticals, GmbH

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2024
• Primary Completion (Actual): March 6, 2025
• Study Completion (Actual): May 1, 2025

Study Registration Dates

• First Submitted: July 25, 2024
• First Submitted That Met QC Criteria: July 30, 2024
• First Posted (Actual): August 1, 2024

Study Record Updates

• Last Update Posted (Actual): May 21, 2025
• Last Update Submitted That Met QC Criteria: May 16, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Mouth Diseases; Stomatognathic Diseases; Arthritis; Joint Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Eye Diseases; Arthritis, Rheumatoid; Xerostomia; Salivary Gland Diseases; Dry Eye Syndromes; Lacrimal Apparatus Diseases; Sjogren's Syndrome
• Other Study ID Numbers: KPL-404-C221; 2024-512986-15-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No